Z-VDVAD-FMK: Irreversible Caspase-2 Inhibitor for Apoptosis Research

Executive Summary: Z-VDVAD-FMK (benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone) is an irreversible, cell-permeable inhibitor of caspase-2 that covalently modifies the active site cysteine, blocking downstream apoptotic events such as cytochrome c release (Li et al., 2025). This reagent exhibits cross-reactivity with caspases 3 and 7, and is routinely used in apoptosis research to distinguish caspase-2-driven cell death from other executioner pathways (APExBIO product page). Typical experimental concentrations range from 25–100 μM in Jurkat T-lymphocytes for 1–22 hours, with solubility confirmed at ≥34.8 mg/mL in DMSO. Z-VDVAD-FMK is supplied at ≥98% purity by APExBIO, with validated protocols for storage and handling. Its application is pivotal in cancer, neurodegenerative, and viral infection models to delineate caspase signaling and mitochondria-driven apoptosis (related article).

Biological Rationale

Caspases are a family of cysteine-aspartic proteases central to programmed cell death (apoptosis). Caspase-2 is an initiator caspase, active early in the intrinsic (mitochondria-mediated) apoptosis pathway (Li et al., 2025). Upon activation, caspase-2 facilitates mitochondrial outer membrane permeabilization, leading to cytochrome c release and downstream effector caspase activation. Dysregulation of caspase-2 activity is linked to cancer progression, neurodegeneration, and viral evasion of host defenses. Pharmacological inhibition of caspase-2 enables researchers to parse its role in cell-fate decisions and pathogenesis, making selective inhibitors such as Z-VDVAD-FMK essential tools (see related discussion).

Mechanism of Action of Z-VDVAD-FMK

Z-VDVAD-FMK is a synthetic peptide analog incorporating a fluoromethyl ketone (FMK) functional group. This group forms a covalent bond with the active site cysteine of caspase-2, resulting in irreversible inhibition (APExBIO). The peptide sequence (Val-Asp-Val-Ala-Asp) mimics the caspase-2 recognition motif, conferring selectivity. Upon entry into the cell, Z-VDVAD-FMK blocks caspase-2-mediated cleavage events, preventing mitochondrial cytochrome c release, DNA fragmentation, and PARP cleavage. Cross-reactivity with caspase-3 and -7 has been documented, though with reduced potency relative to caspase-2. The compound is not active against non-caspase proteases under standard assay conditions.

Evidence & Benchmarks

• Z-VDVAD-FMK at 50 μM reduces caspase-2 and caspase-3 activity in endothelial cells exposed to oxyhemoglobin, with parallel decreases in DNA fragmentation and PARP cleavage (Li et al., 2025).
• In BHK-21 cells, caspase-2 inhibition via Z-VDVAD-FMK blocks degradation of DDX23 protein and suppresses SVA-3A/2B-mediated host defense evasion (Li et al., 2025).
• Experimental use in Jurkat T-lymphocytes at 25–100 μM for 1–22 h yields robust inhibition of caspase-2-dependent apoptosis, with minimal off-target toxicity at these concentrations (APExBIO).
• Solubility in DMSO is maintained at concentrations ≥34.8 mg/mL; stock solutions >10 mM are stable when stored at −20°C for short durations (APExBIO).
• Cross-caspase activity is confirmed by reduction of caspase-3/7 activity in cell-based assays, yet the greatest potency is observed for caspase-2 (see related article).

Applications, Limits & Misconceptions

Z-VDVAD-FMK is primarily used in apoptosis research to dissect the role of caspase-2 in intrinsic cell death pathways. It is applied in cancer models, neurodegenerative disease studies, and viral infection systems to suppress caspase-2-dependent apoptosis. The reagent is also used to confirm the involvement of mitochondrial cytochrome c release and PARP cleavage in cell death mechanisms. APExBIO supplies the compound (SKU A1922) with validated purity and clear handling instructions (product details).

This article extends the analysis found in Strategic Modulation of Apoptosis and Pyroptosis by providing detailed, peer-reviewed benchmarks and clarifying the selectivity and solubility profiles of Z-VDVAD-FMK. For scenario-driven troubleshooting, see Z-VDVAD-FMK: Scenario-Driven Solutions, which focuses on experimental optimization; here we emphasize mechanistic and citation-driven facts. The current review also updates the workflow guidance in Precision Caspase Inhibition in Apoptosis Assays by integrating recent viral-host interaction data from Li et al. (2025).

Common Pitfalls or Misconceptions

• Not selective for all caspases: While Z-VDVAD-FMK targets caspase-2 with high potency, it also inhibits caspases 3 and 7 to a lesser degree, and is not universally selective.
• Solubility limits: The compound is insoluble in water and ethanol, requiring DMSO for preparation; improper dissolution can lead to precipitation or assay artifacts.
• Stability constraints: Stock solutions are not recommended for long-term storage; repeated freeze-thaw cycles reduce activity.
• Non-applicability to pyroptosis: Z-VDVAD-FMK does not inhibit inflammatory caspases (e.g., caspase-1, -4, -5) responsible for pyroptotic cell death.
• Does not block non-caspase proteases: Activity is specific to caspase family cysteine proteases under standard conditions.

Workflow Integration & Parameters

For experimental use, Z-VDVAD-FMK is dissolved in DMSO at concentrations >10 mM, with warming and ultrasonic treatment to enhance solubility. Stock solutions are stored at −20°C and should be aliquoted to avoid repeated thawing. Recommended treatment conditions for apoptosis assays (e.g., Jurkat T-lymphocytes) are 25–100 μM for 1–22 hours. Assays should include appropriate controls for DMSO and parallel caspase activity measurements. The inhibitor is compatible with standard apoptosis readouts, including flow cytometry, Western blot for PARP cleavage, and mitochondrial cytochrome c quantification. For best results, consult the detailed product protocol from APExBIO.

Conclusion & Outlook

Z-VDVAD-FMK enables precise, irreversible inhibition of caspase-2, facilitating the mechanistic dissection of mitochondrial apoptosis in cancer, neurodegenerative, and infectious disease models. Its validated potency, solubility, and cross-caspase activity profile make it a cornerstone for apoptosis research. As emerging data clarify caspase-2’s non-redundant role in host-pathogen interactions (Li et al., 2025), targeted inhibitors like Z-VDVAD-FMK will remain essential for both basic and translational studies. For further reading on advanced applications and troubleshooting, see the APExBIO resource center and related articles above.